Los Angeles Times
From Bloomberg News
Johnson & Johnson’s Janssen unit received a subpoena from the California attorney general’s office over sales and marketing of Risperdal, a schizophrenia drug.
The subpoena was issued in September, Johnson & Johnson said in a regulatory filing. The New Brunswick, N.J.-based company said it was responding.
California authorities asked for documents on “sales and marketing and side effects” of the drug, as well as on “interactions with state officials” in Medicaid, the health insurance program for the poor, the filing said.
J&J shares fell 72 cents to $67.99.